PubMed · 1976 · 28 citations · 0 references
MedicineOncologyPharmacotherapyCancer PharmacologyChemotherapyGastrointestinal OncologyChemotherapy Toxicity ManagementColorectal CancerCombination ChemotherapyGastrointestinal Cancer Pharmacotherapy5-Fluorouracil Therapy5-Fluorouracil TreatmentChemotherapy-induced Gastrointestinal ToxicityCombination Drug TherapyOral Fluoropyrimidines
The Southwest Oncology Group has confirmed the superiority of 5-fluorouracil (5-FU) and methyl-CCNU versus 5-FU weekly as treatment for patients with advanced gastrointestinal cancers. The drug combination produced a PR rate of 29.3% compared to the single-drug arm rate of 10.6%; however, the two-drug arm produced much more toxicity. Despite the improved response rate no improvement in survival was observed.